BioNTech buys mRNA, courtroom rival CureVac in all-stock deal

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation. 

Jun 12, 2025 - 17:40
 0
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation.